1035 / 1578
/
/
Multi-center analysis:
King et al Radiat Oncol 2013
Risk-group Follow-
up
Low
36 mo
Intermediate 31 mo
High
23 mo
1100 patients
8 institutions
All patients enrolled in
phase II studies
Matthias Guckenberger - ESTRO SBRT Course 2017
25
Ø
Promising results in all risk groups but FU still short
Ø
Very few patients in the high-risk group and no further
information about detailed risk
07.09.17
/
/
Antihormonal therapy in SBRT
Matthias Guckenberger - ESTRO SBRT Course 2017
26
Ø
No clear recommendation possible
Ø
Most centers practice SBRT for intermediate risk w/o
antihormonal therapy
CF-RT with >76Gy
Zapatero Lancet Oncol 2015
King Radiat Oncol 2015
MVA in prostate SBRT
07.09.17